PubMed Health⌕ Search

Biomedical subjects

O Mansour

Publications and source records attributed to O Mansour.

12 recordsLinked to original sources
PubMed2006

Consumer impact of an interactive decision aid for rectal cancer patients offered adjuvant therapy.

OBJECTIVE: There is increasing interest in the use of decision aids (DAs) to facilitate patient involvement in clinical decisions. This study explored the views of patients with colorectal cancer and participants in a community bowel screening service regarding an interactive DA concerning adjuvant treatment for rectal cancer, and the impact of the aid on knowledge, anxiety, attitudes and preferences for treatment options. METHOD: Fourteen patients with colorectal cancer participated in four focus groups. Eighty-nine participants in a community bowel screening service completed a questionnaire before and 1 week after viewing the DA. Thirty were randomly selected to participate in a telephone interview to obtain qualitative feedback about the DA. RESULTS: Focus group participants reported using information to evaluate their doctor's care and expertise, or to prepare themselves for future symptoms and side-effects. Most supported the use of a DA and preferred pie charts to convey risk information. Within the community sample, anxiety remained stable and knowledge increased after exposure to the DA. Almost all participants found the DA useful and easy to understand, and felt it would make the process of decision making easier. CONCLUSION: A DA regarding adjuvant therapy for rectal cancer appears to be valued and to produce positive outcomes. A randomized controlled trial of this intervention is now required.

Aged↗
PubMed2000

A simple strategy for breakpoint fragment determination in chronic myeloid leukemia.

Molecular characterization is considered a part of the routine work-up of chronic myeloid leukemia (CML) cases. Southern blot analysis using the universal BCR (UBCR) probe on BglII-digested DNA samples is the most commonly used technique, while employing the human 3' bcr probe (PR-1) is usually considered a complementary tool. In this study, we tried to develop a simple and economic strategy for molecular characterization of CML using the 3' probe as it has been shown to be the one capable of locating the breakpoint site. Seventy-eight cases of CML were studied. Molecular analysis was performed using the Southern blot technique. DNA was digested with Bam HI, BglII, EcoRI, and XbaI. Hybridization was performed using the human 3' bcr (PR-1) probe. BamHI and BglII could differentiate fragment 1 (F1) showing rearrangement (R) with Bam HI and germline configuration (G) with BglII; F2/3 showing R with both, and F4 showing R with BamHI and G with BglII. F2/3 cases were further divided by HindIII enzyme into F2 showing (G) and F3 showing (R). Fragment 0 showed G with both, but R with EcoRI and/or XbaI, while 3' deletion gave G with all four enzymes. Our results showed a relative incidence of 6.4% for F0, 20.5% for F1, 32.1% for F2, 19.2% for F3, 15.4% for F4, and 6.4% for 3' deletion. Sixty cases were evaluated clinically and hematologically and were followed up for disease evolution and survival. They included 32 cases in early chronic phase, 24 in late chronic phase, two in acceleration, and two in blastic crisis. No significant correlation was encountered between the breakpoint site and any of the clinical and hematological data except those patients with 3' deletion who showed a very short survival. The study emphasizes Southern blotting as the method of choice for molecular characterization of CML and offers a simple and economic strategy for diagnosis and determination of breakpoint fragment.

Adolescent↗
PubMed2000

A phase II study of gemcitabine plus cisplatin chemotherapy in advanced bilharzial bladder carcinoma.

Bilharzial bladder cancer represents a distinct clinicopathological entity. To investigate whether gemcitabine-cisplatin is also active against bladder cancer of bilharzial origin, we performed a phase II study of previously untreated patients with stage III/IV disease. Standard eligibility criteria were used. Patients received gemcitabine (1000 mg/m(2)) on days 1, 8 and 15 and cisplatin (70 mg/m(2)) on day 2 of every 28-day cycle. The 32 males and 5 females had a median age of 59 years (range: 29-81 years). Of 33 evaluable patients, 8 (24%) achieved complete responses, and 10 (30%) partial responses, for an overall response rate of 55%. 3 patients had minor responses. Responses were observed at all disease sites including lung and liver lesions. Myelosuppression was significant but manageable. Non-haematological toxicity was limited mainly to nausea and vomiting and raised liver enzymes. Thus, these data suggest that gemcitabine plus cisplatin induces high response rates in patients with bilharzial bladder cancer with a moderate toxicity profile.

Adult↗
PubMed1997

Elevated concentrations of interleukins and leukotriene in response to Mycobacterium tuberculosis infection.

There is significant research in the role of interleukins in lung disease, as the cytokines are important mediators in the host response to mycobacterium tuberculosis infection. Plasma from patients with pulmonary tuberculosis (TB) and healthy controls were investigated for their content of granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-6 (IL-6) and leukotriene B4 (LTB4). LTB4 and IL-6 were measured by enzyme immunoassay after lipid extraction in the case of LTB4 while GM-CSF was measured by enzyme amplified sensitive immunoassay. Significantly elevated concentrations of IL-6 were found in far-advanced lesions of pulmonary tuberculosis patients, P < 0.05. However, nonsignificant increases of IL-6 were obtained in moderate lesions and minimal lesions compared to normal healthy subjects. Marked elevations of LTB4 were found in TB patients, the highest values being shown in patients with far-advanced lesions followed by moderately advanced and minimal lesions in relation to the mean value for normal healthy controls, P < 0.001 for all groups. 93% of the tuberculosis patients showed a higher level of LTB4 above the upper limit of the control group. In contrast there was no significant increase of GM-CSF in any of the TB subgroups. These results suggest that LTB4 and the interleukins may play a role in the pathogenesis of mycobacterium tuberculosis infection.

Adolescent↗
PubMed1996

Urinary gonadotropin peptide (UGP) in Egyptian patients with benign and advanced malignant urological disease.

Urinary gonadotropin peptide (UGP) levels were determined in urine samples from 450 Egyptian subjects to determine its relative level of expression in benign and malignant urological disease, and normal individuals. The mean UGP level in patients with bladder cancer was 44-fold higher than in patients with benign disease, and 81-fold higher than in normal individuals. At specificities of 95% and 100%, overall sensitivities of 73% and 60%, respectively, were observed for the detection of malignant disease. Mean UGP levels in patients with bladder cancer were significantly correlated with the stage and grade of malignant disease but did not vary significantly when stratified according to histological type of disease, nodal involvement or bilharzial association. UGP could be a potentially useful marker for the differentiation of benign from malignant urological disease.

Adult↗
PubMed1993

Clinical value of thymidine kinase and tissue polypeptide specific antigen in breast cancer.

Thymidine kinase (TK) and tissue polypeptide specific antigen (TPS) were determined in breast cancer (BC) patients (n = 83), normal healthy women (n = 30) and 18 women with different benign mastopathies. Mean serum levels of TK and TPS in BC patients showed significant increases from their corresponding levels in healthy women and those with benign breast diseases. Diagnostic sensitivity of TK and TPS was 47% and 58% respectively at the selected cut-off values 8 U/L for TK and 110 U/L for TPS (96% specificity). Pre-operative serum levels of TK and TPS showed significant correlation with the stage of disease and with other classical prognostic factors; clinical stage, tumour size, lymph node involvement and distant metastasis. Nineteen BC patients were followed-up by serial monthly measurements of TK and TPS (4-10 samples). Both markers seemed to be valuable in monitoring drug efficacy. TK and TPS were able to detect systemic recurrence before clinical diagnosis (average 2 months lead time). TPS was greatly affected by liver diseases.

Biomarkers, Tumor↗
PubMedDate not supplied

Diuretic contrast-enhanced magnetic resonance urography versus intravenous urography for depiction of nondilated urinary tracts.

Diuretic contrast-enhanced magnetic resonance urography (MRU) is analogous to conventional intravenous urography (IVU) and, hence, designated as excretory MRU. It is performed with a T1-weighted fast gradient-echo sequence to obtain breath-hold, dynamic MRU after intravenous injection of low-dose furosemide (5-10 mg) and gadolinium (Gd) chelate. The combination of Gd and furosemide is the key for achieving a uniform distribution of the contrast material inside the entire urinary tract. It provides high-resolution images of nondilated urinary tracts and information about the renal function. This pictorial essay reviews the technical aspects and practical consideration of diuretic Gd-enhanced MRU and underlines its diagnostic capability in comparison with IVU in the depiction of nondilated collecting systems. We discuss its potential applications, as in young patients with anatomic anomalies, patients with renal transplants, patients allergic to iodinated contrast medium, and avoiding multimodality work-up in the evaluation of kidney donors and patients with renal and extrarenal tumor diseases.

Adult↗